G1 Therapeutics (GTHX) Set to Announce Quarterly Earnings on Wednesday

G1 Therapeutics (NASDAQ:GTHX) will issue its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Parties that are interested in participating in the company’s conference call can do so using this link.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.06. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The firm had revenue of $14.87 million for the quarter, compared to analysts’ expectations of $12.83 million. During the same period in the prior year, the business posted ($0.73) earnings per share. On average, analysts expect G1 Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

G1 Therapeutics Trading Up 2.2 %

Shares of GTHX opened at $4.19 on Wednesday. The business’s 50-day moving average price is $3.66 and its 200-day moving average price is $2.95. G1 Therapeutics has a twelve month low of $1.08 and a twelve month high of $5.00. The stock has a market cap of $218.84 million, a PE ratio of -4.41 and a beta of 1.73. The company has a quick ratio of 3.45, a current ratio of 3.87 and a debt-to-equity ratio of 1.46.

Wall Street Analyst Weigh In

GTHX has been the subject of several recent analyst reports. Needham & Company LLC reissued a “buy” rating and set a $12.00 price objective on shares of G1 Therapeutics in a report on Friday, April 12th. Wedbush reissued an “outperform” rating and set a $5.00 price objective (up previously from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th.

Insider Transactions at G1 Therapeutics

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $4.62, for a total value of $132,132.00. Following the completion of the sale, the insider now owns 169,938 shares of the company’s stock, valued at $785,113.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.23% of the stock is owned by insiders.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.